Ekso Bionics (NASDAQ:EKSO) Lowered to Sell at Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Ekso Bionics (NASDAQ:EKSO) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “

Several other equities analysts have also recently commented on EKSO. ValuEngine raised Ekso Bionics from a hold rating to a buy rating in a report on Wednesday, December 30th. HC Wainwright cut their target price on Ekso Bionics from $12.00 to $11.00 and set a buy rating for the company in a research note on Friday, October 30th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $8.56.

Shares of NASDAQ:EKSO opened at $8.89 on Wednesday. The company has a market cap of $73.93 million, a P/E ratio of -3.03 and a beta of 2.33. The stock’s 50-day moving average is $6.13 and its 200-day moving average is $5.70. Ekso Bionics has a 52-week low of $2.25 and a 52-week high of $10.74. The company has a debt-to-equity ratio of 0.37, a quick ratio of 3.70 and a current ratio of 4.12.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Thursday, October 29th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.12). The business had revenue of $2.90 million for the quarter, compared to the consensus estimate of $2.43 million. Ekso Bionics had a negative net margin of 140.82% and a negative return on equity of 201.69%. As a group, equities analysts predict that Ekso Bionics will post -1.18 EPS for the current year.

Hedge funds have recently bought and sold shares of the stock. Morgan Stanley increased its stake in shares of Ekso Bionics by 54,764.3% in the 3rd quarter. Morgan Stanley now owns 153,620 shares of the company’s stock valued at $729,000 after buying an additional 153,340 shares during the period. BlackRock Inc. increased its position in Ekso Bionics by 70.9% in the third quarter. BlackRock Inc. now owns 80,135 shares of the company’s stock worth $381,000 after purchasing an additional 33,248 shares during the period. WINTON GROUP Ltd raised its holdings in Ekso Bionics by 39.6% during the 3rd quarter. WINTON GROUP Ltd now owns 27,759 shares of the company’s stock worth $132,000 after purchasing an additional 7,872 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of Ekso Bionics by 2,233.5% in the 2nd quarter. Bank of Montreal Can now owns 18,808 shares of the company’s stock valued at $138,000 after purchasing an additional 18,002 shares during the last quarter. Finally, Natixis bought a new stake in Ekso Bionics in the third quarter valued at about $71,000. Hedge funds and other institutional investors own 14.06% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in the United States and internationally. The company operates in two segments, EksoHealth and EksoWorks. It primarily offers EksoNR, a bionic suit that provides the ability to stand and walk over ground with a full weight-bearing, reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke; and EksoUE, a wearable assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms, as well as reduce fatigue while rehabilitation sessions to achieve a larger active range of motion.

Further Reading: Resistance Level

Get a free copy of the Zacks research report on Ekso Bionics (EKSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.